Idexx Laboratories Inc

Day range

$558.29 – $569.56

Open

$564.80

Prev close

$566.76

Volume

398.28K

Market cap

$44.65B

Shares out

78.78M

P/E

39.18

P/S

9.81

P/B

27.69

P/FCF

35.60

ROE

70.7%

ROA

33.1%

Debt/Equity

0.60

Div yield

0.00%

As of Oct 22, 2026

• Governance documentsMay 15, 2026

  the Corporation's shareholders approved amendments to the Corporation's Amended and Restated Certificate of Incorporation to (i) declassify the Board over a three-year period and provide for the annual election of all directors beginning at the 2029 annual meeting of shareholders and (ii) provide for shareholders owning at least 25% of the shares of the Corporation's capital stock continuously for at least one year the right to have the Corporation call a special meeting of shareholders

• Executive leadershipMar 26, 2026

  Pursuant to the Separation Agreement, IDEXX will pay to Dr. Hunt separation benefits in the form of (i) salary continuation for 104 weeks following the Separation Date, in the aggregate amount of $1,230,000; (ii) Dr. Hunt's target annual bonus for two years, in the aggregate amount of $984,000, payable together with the salary continuation payments, (iii) a lump-sum payment of $50,000, representing 78 weeks of COBRA premium costs with respect to Dr. Hunt's continued coverage under the IDEXX medical, dental and/or vision plans; (iv) transition assistance benefit of $10,000; and (v) reimbursement of tax preparation or financial planning services for the 2025 and 2026 tax years in an amount not to exceed $6,000 per tax year.

• Board of directorsFeb 13, 2026

  On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the "Company") notice of her intention to retire from the Board of Directors (the "Board") effective immediately following the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to be held on May 12, 2026. Ms. Szostak's decision to retire from the Board does not arise from any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, practices or otherwise.

• Executive leadershipJan 13, 2026

  Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the "Company" or "IDEXX") of his intent to step down as the Company's President and Chief Executive Officer effective as of May 12, 2026 (the "Transition Date") and retire from the Company and the Company's Board of the Directors (the "Board") immediately following the Company's annual meeting of shareholders in May 2027 (the "Retirement Date").

• Debt activityNov 13, 2025

  Amendment No. 2 to Fourth Amended and Restated Credit Agreement...entered into Amendment No. 2 (the 'Amendment'), to that certain fourth amended and restated credit agreement relating to a five-year unsecured revolving credit facility in the principal amount of $1.0 billion...and a three-year unsecured term loan in the principal amount of $250 million.

• NVSTEnvista Holdings Corporation Common stock, $0.01 par value per share-1.54%

Days to cover

3.9

Short interest

1.94M

Avg volume

496.27K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
  neutralZacks Investment Research· Oct 23, 2026
• Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
  positiveZacks Investment Research· Oct 23, 2026
• How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
  positiveZacks Investment Research· Oct 21, 2026
• Europe Companion Animal Diagnostics Market Size and Forecast, 2021 - 2031 | AI-Enabled Testing and Preventive Pet Care Fuel 9.5% CAGR and a US$2.27 Billion Opportunity
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
  positiveZacks Investment Research· Oct 20, 2026